Related Experiment Video
Updated: Mar 26, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD
Srinivasan Mukundan1, Michael L Steigner1, Li-Li Hsiao1
1Brigham and Women's Hospital, Boston, MA.
Ferumoxytol, an iron deficiency anemia treatment, serves as a safe MRI contrast agent for patients with chronic kidney disease. Its unique metabolism and long half-life offer diagnostic advantages over gadolinium-based agents.
Area of Science:
- Nephrology
- Radiology
- Pharmacology
Background:
- Ferumoxytol is FDA-approved for iron deficiency anemia in chronic kidney disease (CKD).
- Gadolinium-based contrast agents pose risks (nephrogenic systemic fibrosis) in CKD patients (eGFR < 30 mL/min/1.73 m²).
- Ferumoxytol offers a safer alternative for diagnostic imaging in this population.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies IV: Magnetic Resonance Imaging
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management

